medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2013, Number 3

<< Back Next >>

Alerg Asma Inmunol Pediatr 2013; 22 (3)

1,2,3 Dihydrorhodamine, an accessible and useful technique for the detection of patients and carriers of chronic granulomatous disease. Experience of the Instituto Nacional de Pediatría

Blancas-Galicia L, Espinosa-Padilla SE, Espinosa-Rosales FJ

Language: Spanish
References: 13
Page: 96-100
PDF size: 133.59 Kb.


Text Extraction

Chronic granulomatous disease is a genetic defect in phagocytosis. There is an absence of reactive oxygen species which are essential for the destruction of microorganisms. There are two types of chronic granulomatous disease according to the inheritance pattern, the X-linked recessive and autosomal recessive; the former is the most frequent and severe. There are different techniques for screening the disease. They are based in measuring the production of reactive oxygen species in neutrophils. The reduction of nitroblue tetrazolium and dihydrorhodamine 1,2,3 tecnique are widely used. The latter has the advantage that in addition to be useful as an screening test, it is also useful for detecting the pattern of inheritance and post-transplant chimerism. In this paper we describe the experience of using the dihydrorhodamine in chronic granulomatous disease in Mexico.


REFERENCES

  1. Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol. 2013; doi: 10.1111/cei.12202.

  2. Bustamante J et al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol. 2007; 120(1): 32-38.

  3. Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med. 2010; 68(11): 334-340.

  4. van den Berg JM et al. Chronic granulomatous disease: the European experience. PLoS One. 2009; 4(4): e5234.

  5. Dinauer MC. Chronic granulomatous disease and other disorders of phagocyte function. Hematology Am Soc Hematol Educ Program. 2005; 89-95.

  6. Roesler J et al. Diagnosis of chronic granulomatous disease and of its mode of inheritance by dihydrorhodamine 123 and flow microcytofluorometry. Eur J Pediatr. 1991; 150(3): 161-165.

  7. Baehner RL, Boxer LA, Davis J. The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood. 1976; 48(2): 309-313.

  8. Mauch L et al. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem. 2007; 53(5): 890-896.

  9. Emmendorffer A et al. Evaluation of flow cytometric methods for diagnosis of chronic granulomatous disease variants under routine laboratory conditions. Cytometry. 1994; 18(3): 147-55.

  10. Yu G et al. Focus on FOCIS: the continuing diagnostic challenge of autosomal recessive chronic granulomatous disease. Clin Immunol. 2008; 128(2): 117-126.

  11. Lakshman R et al. Post mortem diagnosis of chronic granulomatous disease: how worth while is it? J Clin Pathol. 2005; 58(12): 1339-1341.

  12. Battersby AC et al. Clinical manifestations of disease in x-linked carriers of chronic granulomatous disease. J Clin Immunol. 2013.

  13. Kim HY et al. Rapid determination of chimerism status using dihydrorhodamine assay in a patient with X-linked chronic granulomatous disease following hematopoietic stem cell transplantation. Ann Lab Med. 2013; 33(4): 288-292.




2020     |     www.medigraphic.com